These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16162973)

  • 1. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
    Knight LA; Conroy M; Fernando A; Polak M; Kurbacher CM; Cree IA
    Anticancer Drugs; 2005 Oct; 16(9):969-76. PubMed ID: 16162973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
    Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA
    BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
    Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
    Invest New Drugs; 2012 Aug; 30(4):1750-5. PubMed ID: 21604021
    [No Abstract]   [Full Text] [Related]  

  • 4. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
    Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
    BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
    Budman DR; Calabro A
    Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
    Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
    Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
    Jagdev SP; Coleman RE; Shipman CM; Rostami-H A; Croucher PI
    Br J Cancer; 2001 Apr; 84(8):1126-34. PubMed ID: 11308265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
    Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
    Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates induce breast cancer cell death in vitro.
    Fromigue O; Lagneaux L; Body JJ
    J Bone Miner Res; 2000 Nov; 15(11):2211-21. PubMed ID: 11092402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
    Ebert R; Meissner-Weigl J; Zeck S; Määttä J; Auriola S; Coimbra de Sousa S; Mentrup B; Graser S; Rachner TD; Hofbauer LC; Jakob F
    Mol Cancer; 2014 Dec; 13():265. PubMed ID: 25496233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells.
    Kars MD; Işeri OD; Ural AU; Gündüz U
    Anticancer Res; 2007; 27(6B):4031-7. PubMed ID: 18225567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.
    Forsea AM; Müller C; Riebeling C; Orfanos CE; Geilen CC
    Br J Cancer; 2004 Aug; 91(4):803-10. PubMed ID: 15280922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
    Räikkönen J; Crockett JC; Rogers MJ; Mönkkönen H; Auriola S; Mönkkönen J
    Br J Pharmacol; 2009 Jun; 157(3):427-35. PubMed ID: 19371349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
    Boissier S; Ferreras M; Peyruchaud O; Magnetto S; Ebetino FH; Colombel M; Delmas P; Delaissé JM; Clézardin P
    Cancer Res; 2000 Jun; 60(11):2949-54. PubMed ID: 10850442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
    Vorotnjak M; Boos J; Lanvers-Kaminsky C
    Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
    Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD
    Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
    Mundy GR; Yoneda T; Hiraga T
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.